Open an account

Regencell Bioscience Holdings

RGC · NASDAQ

$7.67−$2.14 (−21.81%)TodayMarket closed ·
Prev close $9.81

About RGC

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company employs 10 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Employees
10
Headquarters
Hong Kong
Listed
Jul 16, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
regencellbioscience.com

RGC key statistics

Market cap
3.80B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
375.28K
Volume
476.43K
Open price
$9.82
High today
$9.82
Low today
$7.55
52 Week high
$69.00
52 Week low
$4.51

Regencell Bioscience Holdings (RGC) at a glance

As of Oct 23, 2026, Regencell Bioscience Holdings (RGC) shares are priced at $7.67, giving the company a market cap of 3.80B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.55 and $9.82. The current price is 1.6% above the day's low and 21.9% below its high.

Volume so far is 476.43K shares, above the average of 375.28K shares a day.

Over the past year Regencell Bioscience Holdings has ranged from $4.51 to $69.00, and now sits 5% of the way up that range.

RGC news

  • Avi Kapoor

    Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releaseGlobe Newswire

    Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC

  • Press releasePRNewswire

    Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

  • Press releaseBusiness Wire

    Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

  • Press releasePRNewswire

    RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm

  • Press releaseBusiness Wire

    RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

  • Press releaseGlobe Newswire

    REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.